Sitting on a Cash Pile 13.0? This Bio-Tech is Focused on Discovering and Developing Cancer Immunotherapies

Sitting on a Cash Pile 13.0?  This Bio-Tech is Focused on Discovering and Developing Cancer Immunotherapies

#cash #bullish #buy $AFMD Affimed NV (NASDAQ:AFMD) broke out on 10 March at 6.88 and confirmed on 31 March at 7.91. Thus, garnering a LTN Cash Pile Buy rating with a 1 yr price target at 12.54. The Street’s consensus target is at 12.36. AFMD closed Wednesday at 7.91 within 52-wk range of 1.50 – 8.60. The […]